Please join our panel for a review of key enforcement and investigations trends for life sciences, healthcare, and pharmaceutical companies. The panel will identify key government enforcement priorities through an assessment of recent policy announcements from the Department of Justice and other federal regulators, as well as select enforcement actions and recent settlements in these industries. In addition, our panel will discuss emerging trends in conducting internal reviews and government investigations to provide legal and compliance professionals with helpful perspective and strategies for risk mitigation.  Topics covered will include:

• key recent FCA and AKS resolutions, as well as significant recent cases interpreting the FCA’s intent and causation elements;
• the implementation of multiple DOJ voluntary self-disclosure policies in the wake of the DOJ’s 2022 “Monaco Memo”;
• recent DOJ policy changes encouraging companies to “claw back” compensation from executives and employees engaged in wrongdoing; and
• policy changes and emerging trends related to companies’ preservation, review, and production of messaging application data.